July 31, 2023
Life Sciences | Tea Leaves
  • The Food and Drug Administration (FDA) has approved a treatment for the prevention of RSV among infants and toddlers, making it the first preventive drug for the common virus that surged last winter among small children. The FDA approved nirsevimab-alip, or Beyfortus, for the prevention of respiratory syncytial virus (RSV) among newborns and infants born during or entering into their first RSV season, which typically starts in the fall, peaks in the winter and ends in the spring. (Articles hereherehere, and here)